However, definite stent thrombosis occurred only in patients with initial TIMI flow 0/1 (1.0%). After adjustment, preprocedural TIMI flow <3 (versus 3) was not an independent predictor of major adverse ischemic events within 30 days (odds ratio 1.89, 95% confidence interval 0.74-4.85). 30) were highest in patients with TIMI flow 0/1. At 30 days, the composite ischemic endpoint (5.5, 2.9, and 2.1%, p <. For this analysis, patients were divided into three groups according to the preprocedural TIMI flow grade of the infarct vessel: TIMI 0/1, TIMI 2, and TIMI 3.įrom a total of 1,680 patients, 1,113 had TIMI 0/1, 279 TIMI 2, and 288 TIMI 3 flow before primary PCI. The ATLANTIC study compared prehospital versus inhospital treatment with ticagrelor in patients with acute STEMI. However, it is unclear whether the same is true in patients with ongoing STEMI of less than 6 hr duration, rapid reperfusion, and modern guideline-adherent therapy. Previous studies have shown that the TIMI flow 0/1 prior to primary percutaneous coronary intervention (PCI) is associated with a poor clinical outcome. This study sought to analyze the impact of the preprocedural thrombolysis in myocardial infarction (TIMI) flow on clinical outcome in patients with ST-elevation myocardial infarction (STEMI). 9 Department of Interventional Cardiology, Maastricht University Medical Centre, Maastricht, the Netherlands.8 Department of Cardiology, Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany.7 Sorbonne Université, ACTION Study Group, Institut de Cardiologie (AP-HP), Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France.6 3rd Department of Medicine, Cardiology and Intensive Care Medicine, Wilhelminen Hospital, and Sigmund Freud Private University, Medical School, Vienna, Austria.5 Heart Disease Institute, Hospital Universitario de Bellvitge, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
4 Cardiovascular and Neurological Department, Azienda Ospedaliera Arezzo, Arezzo, Italy.3 Unite de Recherche Clinique, Hôpital Lariboisière, ACTION Study Group, Université Paris 7, Paris, France.2 Department of Cardiology, Heart Center Ludwigshafen, Ludwigshafen, Germany.1 Department of Cardiology, University Clinic Giessen, Germany.
0 kommentar(er)
